Claims

1. A compound of the formula



I

wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, X is C_1-C_{18}-alkylene which optionally can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1, in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof.

2. A compound in accordance with claim 1, wherein R is isopropyl.

3. A compound in accordance with claim 2, wherein R^3 is hydroxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy or lower-alkylaminocarbonyloxy.

4. A compound in accordance with claim 3, wherein R^3 is isobutyryloxy, methoxyacetyloxy or butylaminocarbonyloxy.

5. A compound in accordance with claim 1, wherein n is the number 1.

6. A compound in accordance with claim 1, wherein R^1 is fluorine.

7. A compound in accordance with claim 1, wherein R^2 is methyl.

8. A compound in accordance with claim 1, wherein X is C_3-C_7-alkylene.

9. A compound in accordance with claim 8, wherein X is propylene, butylene, pentamethylene or hexamethylene.

10. A compound in accordance with claim 1, wherein A is 2-benzimidazolyl, 2-benzthiazolyl, 1-methyl-2-benzimidazolyl, 1-dodecyl-2-benzimidazolyl, benzimidazolonyl, 2,3,4,5-tetrahydro-4-methylbenzodiazepine-2,5-dion-1-yl, 6-chloro-2,3,11,11a-tetrahydro-pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl or 1-methyl-4,5-diphenyl--2-imidazolyl.

11. A compound in accordance with claim 10, wherein A is 2-benzimidazolyl or 2-benzthiazolyl.

12. A compound in accordance with claim 1, wherein R is isopropyl, R^3 is hydroxy, isobutyryloxy, methoxyacetyloxy or butylaminocarbonyloxy, R^1 is fluorine, R^2 is methyl, X is propylene, butylene, pentamethylene or hexamethylene, A is 2-benzimidazolyl or 2-benzthiazolyl and n is the number 1.

13. A compound in accordance with claim 1, 2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]-ethyl]-6-fluoro-1,2,3,4-tetrahydro-1α-isopropyl-2α--naphthyl methoxyacetate.

14. A compound in accordance with claim 1, [1S,2S]-2-[2-[[5-(2-benzthiazolyl)pentyl]methyl-amino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2--naphthyl methoxyacetate.

15. A compound in accordance with claim 1, [1S,2S]-2-[2-[[3-(2-benzimidazolyl)propyl]-methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1--isopropyl-2-naphthyl methoxyacetate.

16. A composition with calcium antagonistic activity comprising an effective amount of a compound of the formula



I

wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyl oxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, X is C_1-C_{18}--alkylene which optionally can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimida-zolonyl, imidazo[4,5-c]pyridinyl, imidazo-[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-

-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11--dion-10-yl and n is the number 0 or 1, in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof, and a pharmaceutically inert excipient.

17. A composition in accordance with claim 16, wherein R is isopropyl, R^3 is hydroxy, isobutyryloxy, methoxyacetyloxy or butylaminocarbonyloxy, R^1 is fluorine, R^2 is methyl, X is propylene, butylene, pentamethylene or hexamethylene, A is 2-benzimidazolyl or 2-benzthiazolyl and n is the number 1.

18. A composition in accordance with claim 17, wherein the compound of formula I is [1S,2S]-2-[2-[[3--(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro--1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methyoxyacetate or its racemate.

19. A method of treating or preventing angina pectoris, ischaemia, arrhythmias, high blood pressure and cardiac insufficiency which comprises administering to a warm-blooded animal in need of such treatment, an effective amount of a compound of the formula



I

wherein R is lower-alkyl, R^1 is halogen, R^2 is C_1-C_{12}-alkyl, R^3 is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, X is C_1-C_{18}--alkylene which optionally can be interrupted by

1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo-[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5--dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11--dion-10-yl and n is the number 0 or 1,

in the form of a racemate or an optical antipode, an N-oxide, or a pharmaceutically usable acid addition salt thereof.

20. A method in accordance with claim 19, wherein R is isopropyl, R^3 is hydroxy, isobutyryloxy, methoxyacetyloxy or butylaminocarbonyloxy, R^1 is fluorine, R^2 is methyl, X is propylene, butylene, pentamethylene or hexamethylene, A is 2-benzimidazolyl or 2-benzthiazolyl and n is the number 1.

21. A method in accordance with claim 20, wherein the compound of formula I is [1S,2S]-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate or its racemate.

***